Gastrointestinal Perforation After Treatment With Tocilizumab

Abstract

Get full access to this article

View all access options for this article.

References

Sheppard

Laskou

Stapleton

PP.

Hadavi

Dasgupta

. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972-1988.doi:10.1080/21645515.2017.1316909

http://www.ncbi.nlm.nih.gov/pubmed/28841363

Xie

Yun

Bernatsky

Curtis

. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612-2617.doi:10.1002/art.39761

http://www.ncbi.nlm.nih.gov/pubmed/27213279

Luo

Liu

Qiu

et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020 [Epub ahead of print]. 06 Apr 2020.doi:10.1002/jmv.25801

http://www.ncbi.nlm.nih.gov/pubmed/32253759